The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.

This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms of glaucoma and screen for therapeutic agents. Glaucoma, a leading cause of blindness, is often associated with mutations in the myocilin gene, but the exact mechanisms by which these mutations lead to cell death are not fully understood. By utilizing these cell lines, researchers can investigate how mutant myocilin induces endoplasmic reticulum stress and apoptosis, particularly under oxidative stress conditions. This understanding could pave the way for the development of targeted therapies that mitigate the effects of these mutations and improve patient outcomes.